Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | APAF1 | O14727 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
| ▸ | TSSK1B | Q9BXA7 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Calanolide B SCHEMBL212038 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Costatolide SCHEMBL30544160 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| (-)-Calanolide A SCHEMBL29803798 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Calanolide A SCHEMBL140017 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Calanolide A SCHEMBL30075237 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| (-)-Calanolide A SCHEMBL8927754 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Costatolide SCHEMBL29397227 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Costatolide SCHEMBL29402951 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| Costatolide SCHEMBL8927756 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL19596735 | 0.90 | ALDH1A1 (0.82) | ALDH1A1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143952-B1 | METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS | SARAWAK MEDICHEM PHARMACEUTICALS INC (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1143952-A3 | METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS | Sarawak Medichem Pharmaceuticals Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020013478-A1 | Calanolide analogues and methods of their use | SARAWAK MEDICHEM PHARMACEUTICALS,INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1143952-A2 | METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS | Sarawak Medichem Pharmaceuticals Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-20010027209-A1 | Method and composition for treating and preventing mycobacterium infections | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2001-10-04 | — | — | US | disclosed |
| US-6277879-B1 | VIRICIDES | SARAWAK MEDICHEM PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| US-6268393-B1 | CALANOLIDES AND ANALOGUES THEREOF | SARAWAK MEDICHEM PHARMACEUTICALS | 2001-07-31 | — | — | US | disclosed |
| WO-2000021514-A2 | METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5981770-A | HIV REVERSE TRANSCRIPTASE INHIBITOR, VIRICIDE | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5977385-A | VIRICIDES | SARAWAK MEDICHEM PHARMACEUTICALS (US) | 1999-11-02 | — | — | US | disclosed |
| US-5892060-A | REVERSE TRANSCRIPTASE INHIBITOR; AIDS THERAPY | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5872264-A | BENZO(1,2-B:5,6--B?)TRIPYRAN-2,12-DIONES | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5859050-A | ADMINISTERING TO PREVENT OR TREAT A VIRAL INFECTION | SARAWAK MEDICHEM PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998038193-A1 | METHOD FOR THE PREPARATION OF (+)-CALANOLIDE A AND ANALOGUES THEREOF | MEDICHEM RESEARCH, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| EP-0674643-A1 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0674643-A4 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-08-08 | — | — | EP | disclosed |
| CN-1096786-A | Be used as the coumarin derivatives of retroviral inhibitors | SMITHKLINE BEECHAM CORP (US) | 1994-12-28 | — | — | CN | disclosed |
| WO-1994014789-A1 | COUMARIN DERIVATIVES AS RETROVIRAL INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027209-A1 | Method and composition for treating and preventing mycobacterium infections | CYP51A1, DHCR7, CYP27A1 | ALDH1A1 2628/4885CA12 2752/4885CA1 4388/4885 |
| US-20020013478-A1 | Calanolide analogues and methods of their use | HAVCR2, ZC3HAV1, CYP51A1 | ALDH1A1 3786/4885CA12 957/4885CA1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.